Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
238.98(c) 242.31(c) 243.72(c) 241.17(c) 243.75(c) Last
2 545 987 1 573 492 1 537 772 1 717 891 1 956 569 Volume
+0.46% +1.39% +0.58% -1.05% +1.07% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 27 366 M - -
Net income 2021 6 489 M - -
Net Debt 2021 11 548 M - -
P/E ratio 2021 34,1x
Yield 2021 1,35%
Sales 2022 28 057 M - -
Net income 2022 7 252 M - -
Net Debt 2022 10 319 M - -
P/E ratio 2022 29,8x
Yield 2022 1,49%
Capitalization 221 B 221 B -
EV / Sales 2021 8,50x
EV / Sales 2022 8,24x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ELI LILLY AND COMPANY
10/20ELI LILLY AND : FCA And AKS Claim Founded On Free Pharmaceutical Product Education Dismiss..
AQ
10/19ELI LILLY AND : Tirzepatide results published in The Lancet show superior A1C and body wei..
PR
10/19Eli Lilly and Company Provides Tirzepatide Results
CI
10/18ELI LILLY AND : Declares Q4 Dividend of $0.85 a Share, Payable Dec. 10 to Shareholders of ..
MT
10/18ELI LILLY AND : Lilly Declares Fourth-Quarter 2021 Dividend
PR
10/18Eli Lilly and Company Declares Dividend for the Fourth Quarter of 2021, Payable on Dece..
CI
10/14ELI LILLY AND : Releases Updated Data From Phase 3 Breast Cancer Trial
MT
10/14ELI LILLY AND : Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Dat..
PR
10/14Eli Lilly and Company Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial ..
CI
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
10/13ELI LILLY AND : Combination Therapy Receives FDA Approval as Adjuvant Treatment for Certai..
MT
10/13ELI LILLY AND : FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibito..
PR
10/13FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain..
CI
10/13ELI LILLY : FDA Approves Verzenio in Some High-Risk Early Breast-Cancer Patients
DJ
10/13Hemogenyx Pharmaceuticals plc Announces CDX Licence Agreement
CI
More news
News in other languages on ELI LILLY AND COMPANY
10/19ELI LILLY : résultats encourageants dans le diabète de type 2
10/18Eli Lilly and Company déclare un dividende pour le quatrième trimestre de 2021, payable..
10/14Eli Lilly publie les données actualisées de l'essai de phase 3 sur le cancer du sein
10/13Agilent Technologies et Eli Lilly obtiennent le feu vert de la FDA pour un test de dépi..
10/13ELI LILLY : nouvelle indication de la FDA pour Verzenio
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 243,75 $
Average target price 269,42 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY44.37%220 979
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
MERCK & CO., INC.-0.77%205 472